Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference

Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD), focused on inhaled therapeutic products for endocrine and orphan lung diseases, announced that CEO Michael Castagna will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 1:40 pm (ET). Interested parties can access the live webcast through the Company’s website, with the replay available for 14 days post-event. MannKind aims to develop innovative therapies for conditions like diabetes and pulmonary arterial hypertension using advanced delivery systems.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 1:40 pm (ET).

Interested parties can access a link to the webcast from the New & Events section of the Company’s website at https://investors.mannkindcorp.com/events-and-presentations. The webcast replay will remain available for 14 days following the live presentation.

About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, Twitter or Instagram.

MannKind Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com

FAQ

What announcement did MannKind Corporation make on February 10, 2023?

MannKind Corporation announced that CEO Michael Castagna will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on February 15, 2023.

Where can I watch the MannKind Corporation Fireside Chat?

The MannKind Corporation Fireside Chat can be accessed via a webcast link on the Company's website.

What is the purpose of MannKind's participation in the SVB Securities Global Biopharma Conference?

MannKind aims to discuss its innovative therapeutic products and advancements in inhalation technology at the conference.

How long will the webcast replay of MannKind's presentation be available?

The webcast replay will be available for 14 days following the live presentation.

What is the focus of MannKind Corporation's product development?

MannKind specializes in developing inhaled therapeutic products for endocrine and orphan lung diseases.